Evidence map›Paper›PMID 41026281›Full record

ArticleDiscover oncology2025

Isoquercitrin triggers the ferroptosis of ovarian cancer via SLC7A11-dependent manner to repress its tumorigenesis.

Xiaolong Zhang, Youzhen Luo, Qiaoling Gao, Zhisheng Huang, Caihong Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaolong ZhangDepartment of Gynecology, The First College of Clinical Medical Science, Yichang Central People's Hospital, China Three Gorges University, Yichang, 443003, China.
Youzhen LuoDepartment of Gynecology, The First College of Clinical Medical Science, Yichang Central People's Hospital, China Three Gorges University, Yichang, 443003, China.
Qiaoling GaoDepartment of Gynecology, The First College of Clinical Medical Science, Yichang Central People's Hospital, China Three Gorges University, Yichang, 443003, China.
Zhisheng HuangDepartment of Gynecology, The First College of Clinical Medical Science, Yichang Central People's Hospital, China Three Gorges University, Yichang, 443003, China.
Caihong LiDepartment of Gynecology, The First College of Clinical Medical Science, Yichang Central People's Hospital, China Three Gorges University, Yichang, 443003, China. licaihong99@sina.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isoquercitrin (ISOQ) has been identified to exert notable inhibitory effects on tumorigenesis, though its role on ovarian cancer is unknown. Here, this present research focused on the role of ISOQ on ovarian cancer tumorigenesis and investigated its mechanism. Results unveiled that ISOQ dose-dependently repressed the proliferation and migration, and triggered the ferroptosis of ovarian cancer cells. Mechanistically, SLC7A11 functioned as the target of ISOQ, and ISOQ repressed the SLC7A11 expression of ovarian cancer cells. Rescue assays indicated that ISOQ/SLC7A11 accelerated the ferroptosis of ovarian cancer cells. In vivo, ISOQ repressed the tumorigenesis of ovarian cancer cells. Overall, these findings unveiled that ISOQ triggered the ferroptosis of ovarian cancer via SLC7A11-depedent manner to repress its tumorigenesis.

Indexed as

Ferroptosis.IsoquercitrinOvarian cancerSLC7A11

Identifiers

PMID41026281
PMCPMC12484485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.